Navigation Links
Weikang Bio-Technology Announces Fiscal 2010 Financial Results
Date:3/22/2011

80,019Account receivable652,167-Advances to suppliers and other receivables241,34226,079Inventory388,535285,395Deferred compensation902,226-Total current assets52,548,08211,691,493NONCURRENT ASSETSDeferred compensation-noncurrent16,077-Property and equipment, net9,606,26910,162,946Construction in progress683,830-Intangible assets15,754,66615,558,731Total noncurrent assets26,060,84225,721,677TOTAL ASSETS$
78,608,924$
37,413,170LIABILITIES AND STOCKHOLDERS' EQUITYCURRENT LIABILITIESAccounts payable$
4,204$
2,668Unearned revenue528,48511,716Taxes payable6,269,4222,247,410Accrued expenses1,376,154-Due to related party25,669-Total current liabilities8,213,9342,271,794ADVANCE FROM OFFICER-650,000OTHER LIABILITY-7,620,321CONTINGENCIES DEFERRED TAX LIABILITY3,464,8153,450,005STOCKHOLDERS' EQUITYCommon stock,  $.00001 par value;  authorized shares ,000,000;  issued and outstanding shares 29,963,551 and 25,486,800 at December 31, 2010 and 2009, respectively

300255Additional paid in capital17,530,601139,245Statutory reserve2,431,9271,069,507Accumulated other comprehensive income2,524,566844,526Retained earnings 44,442,78121,367,517Total stockholders' equity 66,930,17523,421,050TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$
78,608,924$
37,413,170WEIKANG BIO-TECHNOLOGY GROUP CO, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS YEARS
 ENDED DECEMBER 31,20102009CASH FLOWS FROM OPERATING ACTIVITIES:Net income $
24,437,684$
5,616,802Adjustments to reconcile net income to net cashprovided by operating activities:Depreciation and amortization1,193,0451,176,909Stock compensation 3,843,732139,500Stock option35,132-Changes in deferred tax(90,241)(104,306)(Increase) decrease in current assets:Accounts receivable(638,024)-Advances to suppliers and other receivables(214,767)(1,903)Inventory (92,239)(133,257)Increase (decrease) in current liabilities:Accounts pay
'/>"/>

SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance
2. Weikang Bio-Technology to Present at Rodman and Renshaws Annual Global Investment Conference on September 14th 2010
3. Weikang Bio-Technology Reports Second Quarter 2010 Financial Results
4. ICAP Ocean Tomo Announces the Auction of an Improved Compact, Portable Nebulizer Developed and Patented by Tidal Air
5. American Oriental Bioengineering Announces US$20 Million Share Repurchase Program
6. Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
7. Cord Blood America Announces Affiliate Program to Educate on Value of Umbilical Cord Blood Stem Cell Storage
8. Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science
9. Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform
10. Accumetrics Announces Publication of GRAVITAS Primary Results in JAMA
11. Seattle BioMed Announces Major Scientific Expansion, New Addition to Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient Outcome ... myPROpad™ ePRO tablet with the addition of a touchscreen ... widely used and well-respected Patient Reported Outcome (PRO) instruments ... used during clinical trials and in other health care ... to demonstrate Health-Related Quality of Life outcomes (HRQoL) resulting ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced two ... adding to the company’s extensive line-up of HPLC ... operating environment, and full automation, the i-Series provides ... conventional to ultra-high-speed analysis. , The ... so users can begin building the lab of ...
(Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... ROCKVILLE, Md., Aug. 3, 2011 Neuralstem, Inc. (NYSE ... U.S. Department of Defense (DOD) contract to develop its ... cancerous brain tumors. The research contract, entitled "Research to ... be carried out in collaboration with Principal Investigator John ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today ... Monday, August 8, 2011, after the U.S. financial markets close. ... on Monday, August 8, 2011, at 5:00 p.m. Eastern Daylight ... highlights.  A live webcast of the call will be available ...
... CAMBRIDGE, Mass., Aug. 2, 2011 Pathogenica, Inc. announced ... is speaking today at the IBC Life Sciences Drug ... During the conference, the only event on the ... development, and patient care, Dr. Doran will speak on ...
Cached Biology Technology:Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results 2Pathogenica CSO Speaks at IBC Life Sciences Drug Discovery & Diagnostic Development Week 2
(Date:8/20/2014)... have developed methods for electronically manipulating the flight muscles ... use to control those muscles. The work opens the ... for use in emergency response. , "In the big ... the movement of moths for use in applications such ... an assistant professor of electrical and computer engineering at ...
(Date:8/20/2014)... , Aug. 20, 2014  The second ... place in Tampa, Florida ... sessions with Steven Rahman, Director, Technology and Strategy at ... at Experian. The theme of this year,s event ... Privacy. "Biometrics UnPlugged: Mobility at ...
(Date:8/19/2014)... supermarkets to encourage healthier spending habits? A new study ... question by tracking the purchasing records in a supermarket ... the nutritional value of foods for sale. , The ... PhD, and Brian Wansink PhD, author of Slim by ... Hannaford Supermarkets in the Northeastern United States between January ...
Breaking Biology News(10 mins):Research paves way for development of cyborg moth 'biobots' 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... called ,pestilences, three are historically recognized as due to ... 19th to 21st centuries AD there were microbiological evidences ... pestis . "For a long time scholars from different ... of the past pandemics. Only ancient DNA analyses carried ...
... , May 9, 2013 Wexford Science & ... in the Wake Forest Innovation Quarter , today ... buildings currently underway represents an additional $150 million investment ... Wexford,s total investment in the Innovation Quarter to more ...
... NY and San Diego, CA A large, multi-institutional research ... a sweeping analysis in the current issue of the journal ... off to direct early human development. Led by Bing Ren ... The Salk Institute for Biological Studies and James Thomson of ...
Cached Biology News:Scientists confirm that the Justinianic Plague was caused by the bacterium Yersinia pestis 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 2Wexford Science & Technology Makes $150 Million Investment in Wake Forest Innovation Quarter 3Mapping the embryonic epigenome 2Mapping the embryonic epigenome 3
... enables sensitive, fast and specific detection of ... Short hybridisation time ( ... spreads Multiplex capability Available with ... Probes available with different labels. ...
... Source rat adult and fetal ... $550.00, * T75 plated cells ... * This product requires Celprogen ... M55007-08 and extracellular matrix, * ...
... Isolation Kit provides a rapid method for ... from the various bacterial species found within ... of genomic DNA from both gram negative ... ,Purification is based on spin column ...
...
Biology Products: